Springworks Therapeutics

Alternate names: SpringWorks Therapeutics Inc, SpringWorks Therapeutics Inc., SpringWorks Therapeutics, Inc., SpringWorks

Country: US

ROR: 0466xvm69

Crossref ID: 100020337

DOI: 10.13039/100020337

OpenAlex ID: F4320319694

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

2022 · Margaret von Mehren, John M. Kane, et al. · Journal of the National Comprehensive Cancer Network · 1,227

PDF

Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

2021 · A. Gronchi, A.B. Miah, et al. · Annals of Oncology · 1,171

PDF

Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

2021 · P.G. Casali, J.Y. Blay, et al. · Annals of Oncology · 668

PDF

Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

2021 · S.J. Strauss, A.M. Frezza, et al. · Annals of Oncology · 545

PDF

The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients

2020 · Ben Alman, Steven Attia, et al. · European Journal of Cancer · 539

PDF

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

2024 · Matthew Holderfield, Bianca J. Lee, et al. · Nature · 418

PDF

Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts

2021 · Jeffrey J. Quinn, Matthew G. Jones, et al. · Science · 328

PDF

Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

2022 · Scott R. Plotkin, Ludwine Messiaen, et al. · Genetics in Medicine · 319

PDF

Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)

2021 · A. Ferrari, D. Stark, et al. · ESMO Open · 317

PDF

Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors

2023 · Mrinal Gounder, Ravin Ratan, et al. · New England Journal of Medicine · 300

PDF

A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials

2021 · Luca Sforzini, Courtney Worrell, et al. · Molecular Psychiatry · 242

PDF

Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

2021 · S. Stacchiotti, A.B. Miah, et al. · ESMO Open · 216

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

2020 · Rajen Mody, Alice L. Yu, et al. · Journal of Clinical Oncology · 210

PDF

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

2023 · Nicolas Gazeau, Emily C. Liang, et al. · Transplantation and Cellular Therapy · 196

Rewiring cancer drivers to activate apoptosis

2023 · Sai Gourisankar, Andrey Krokhotin, et al. · Nature · 179

PDF

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer

2022 · Craig M. Goodwin, Andrew M. Waters, et al. · Cancer Research · 176

PDF

ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1

2023 · Charlotte Carton, D. Gareth Evans, et al. · EClinicalMedicine · 171

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

2024 · Andrea J. Bullock, Benjamin L. Schlechter, et al. · Nature Medicine · 168

PDF

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

2023 · Lisa B. Leypoldt, Diana Tichy, et al. · Journal of Clinical Oncology · 166

PDF

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

2020 · Lorenzo D’Ambrosio, Nathan Touati, et al. · Cancer · 155

PDF

Keeping people with epilepsy safe during the COVID-19 pandemic

2020 · Jacqueline A. French, Martin J. Brodie, et al. · Neurology · 137

ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma

2024 · Isabel Arrillaga-Romany, Sharon L. Gardner, et al. · Journal of Clinical Oncology · 136

PDF

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma

2024 · Christopher L. Moertel, Angela C. Hirbe, et al. · Journal of Clinical Oncology · 134

PDF

Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

2023 · J.-Y. Blay, M. von Mehren, et al. · ESMO Open · 131

PDF

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

2023 · Timothy A. Yap, Elisa Fontana, et al. · Nature Medicine · 130

PDF

Works count: 410

Citation count: 14,640

H-index: 59

I10-index: 183

2-year mean citedness: 13.17

Awards count: 1